Abstract
Acute respiratory distress syndrome (ARDS) is a common and important clinical problem. Structural damage and functional impairments of the alveolar-capillary membrane components form the core elements of ARDS pathobiology, that results in life-threatening respiratory failure. Continuing lack of pharmacological treatments that could improve outcomes for patients with ARDS highlights the need to better understand ARDS pathobiology by developing and interrogating new tools that mimic the complex human lung architecture. The human ex vivo lung perfusion (EVLP) model is one such tool. The benefits of immunomodulation in Coronavirus disease 2019 (COVID-19) suggests that better delineation of the ARDS lung immune architecture could lead to the discovery of novel targets and enhance our ability to repurpose existing drugs. In this context, our chapter explores how EVLP models could inform ARDS pathobiology and facilitate accelerated translation of preclinical research. We highlight the considerable differences in EVLP models used across studies, which could alter the inferences made about ARDS pathobiology.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307:2526–33.
Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315:788–800.
Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. Lancet. 2010;376:1339–46.
Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364:1293–304.
Saha R, Assouline B, Mason G, Douiri A, Summers C, Shankar-Hari M. Impact of differences in acute respiratory distress syndrome randomised controlled trial inclusion and exclusion criteria: systematic review and meta-analysis. Br J Anaesth. 2021;127:85–101.
Matthay MA, Folkesson HG, Clerici C. Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev. 2002;82:569–600.
Capelozzi VL. What have anatomic and pathologic studies taught us about acute lung injury and acute respiratory distress syndrome? Curr Opin Crit Care. 2008;14:56–63.
Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5:18.
Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med. 2013;187:751–60.
Weathington NM, Alvarez D, Sembrat J, et al. Ex vivo lung perfusion as a human platform for preclinical small molecule testing. JCI Insight. 2018;3:e95515.
Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;2:319–23.
Cypel M, Yeung JC, Hirayama S, et al. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant. 2008;27:1319–25.
Steen S, Sjöberg T, Pierre L, Liao Q, Eriksson L, Algotsson L. Transplantation of lungs from a non-heart-beating donor. Lancet. 2001;357:825–9.
Luo Q, Zhu L, Wang Y, Wang L, Lv W, Hu J. The conversional efficacy of ex vivo lung perfusion and clinical outcomes in patients undergoing transplantation of donor lungs by ex vivo lung perfusion: a meta-analysis. Ann Transplant. 2019;24:647–60.
Cardenes N, Sembrat J, Noda K, et al. Human ex vivo lung perfusion: a novel model to study human lung diseases. Sci Rep. 2021;11:490.
Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A. 2009;106:16357–62.
Ross JT, Nesseler N, Leligdowicz A, et al. The ex vivo perfused human lung is resistant to injury by high-dose S. pneumoniae bacteremia. Am J Physiol Lung Cell Mol Physiol. 2020;319:L218–27.
Gennai S, Monsel A, Hao Q, Park J, Matthay MA, Lee JW. Microvesicles derived from human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Transplant. 2015;15:2404–12.
Park J, Kim S, Lim H, et al. Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia. Thorax. 2019;74:43–50.
McAuley DF, Cross LM, Hamid U, et al. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2017;5:484–91.
Cypel M, Feld JJ, Galasso M, et al. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-Centre, pilot trial. Lancet Respir Med. 2020;8:192–201.
Yeung JC, Cypel M, Machuca TN, et al. Physiologic assessment of the ex vivo donor lung for transplantation. J Heart Lung Transplant. 2012;31:1120–6.
Shaver CM, Wickersham N, McNeil JB, et al. Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury. JCI Insight. 2018;3:e98546.
Snyder ME, Sembrat J, Noda K, et al. Human lung-resident macrophages colocalize with and provide costimulation to PD1(hi) tissue-resident memory T cells. Am J Respir Crit Care Med. 2021;203:1230–44.
Kulkarni HS, Lee JS, Bastarache JA, et al. Update on the features and measurements of experimental acute lung injury in animals: an official American Thoracic Society workshop report. Am J Respir Cell Mol Biol. 2022;66:e1–e14.
Korovesi I, Papadomichelakis E, Orfanos SE, et al. Exhaled breath condensate in mechanically ventilated brain-injured patients with no lung injury or sepsis. Anesthesiology. 2011;114:1118–29.
Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation. 1998;65:1533–42.
Gori F, Fumagalli J, Lonati C, et al. Lung biomolecular profile and function of grafts from donors after cardiocirculatory death with prolonged donor warm ischemia time. J Clin Med. 2022;11:3066.
Wong A, Liu M. Inflammatory responses in lungs from donation after brain death: mechanisms and potential therapeutic targets. J Heart Lung Transplant. 2021;40:890–6.
Sadaria MR, Smith PD, Fullerton DA, et al. Cytokine expression profile in human lungs undergoing normothermic ex-vivo lung perfusion. Ann Thorac Surg. 2011;92:478–84.
Wong A, Zamel R, Yeung J, et al. Potential therapeutic targets for lung repair during human ex vivo lung perfusion. Eur Respir J. 2020;55:902222.
Acknowledgement
MS-H is funded by a clinician scientist fellowship from the National Institute for Health Research [CS-2016-16-011].
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Abdalla, A., Dhaliwal, K., Shankar-Hari, M. (2023). Ex Vivo Lung Perfusion Models to Explore the Pathobiology of ARDS. In: Vincent, JL. (eds) Annual Update in Intensive Care and Emergency Medicine 2023. Annual Update in Intensive Care and Emergency Medicine. Springer, Cham. https://doi.org/10.1007/978-3-031-23005-9_9
Download citation
DOI: https://doi.org/10.1007/978-3-031-23005-9_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-23004-2
Online ISBN: 978-3-031-23005-9
eBook Packages: MedicineMedicine (R0)